NCT07298993Enrolling by invitationPhase 4
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
Determining Evidence in a Placebo-Controlled, Randomized Experiment Studying Continuation vs. Removal of Inessential Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life. Participants will be randomly assigned to one of two groups: Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses. Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules. All participants will: * Take study medicine for about 4 months * Have their blood pressure and heart rate monitored * Complete regular phone calls and questionnaires about how they are feeling This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- 2 Feb 2026
- Primary completion date
- 30 Apr 2029
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- Heart failure
- NCT number
- NCT07298993
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 240
- From 2 Feb 2026 to the primary completion date, 30 Apr 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Compelling guideline indication for ß-blocker:
- Prior EF \<50% (i.e., based on the structured data field on transthoracic echocardiogram)
- Current anginal symptoms (i.e., based on the Rose Angina single-question screener for angina)
- MI (i.e., diagnostic codes) and/or coronary revascularization (i.e., procedure codes) within 3 years
- Hospitalization for a primary discharge diagnosis of atrial fibrillation or atrial flutter with a rapid ventricular response in the prior 12 months (i.e., not for an elective procedure such as a cardioversion or an ablation)
- Other documented reason in the opinion of the treating provider and/or enrolling clinician-investigator
Other illness
- Alternative etiologies of HFpEF syndrome
- Diagnosed dementia (i.e., diagnostic codes)
Other
- Hospitalization for a primary discharge diagnosis of HF within the past 30 days.
- Estimated life expectancy \<6 months (i.e., diagnostic codes)
- Unable to provide informed consent
- Loss of Kaiser Permanente Northern California Membership
Who the study is looking for
- Ambulatory adults age ≥60 years with HFpEF (EF ≥50% based on most recent transthoracic echocardiogram)
- Evidence of HF, defined by at least one of the following:
- Hospitalized with HF in the past 24 months (defined by diagnostic codes in any position)
- BNP \>100 pg/mL in the past 24 months
- Taking any of the following ß-blockers: atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate (i.e., pharmacy prescription data)
- Kaiser Permanente Northern California Membership
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kaiser Permanente Northern California (KPNC) Coordinator of this site? Confirm its status | Pleasanton | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.